Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes - 28/02/18
Doi : 10.1016/j.jaci.2017.12.965
Dmitry Galkin, DrMD, PhD 1, Mark C. Liu, DrMD, FAAAAI 2, Bradley E. Chipps, DrMD 3, Kenneth R. Chapman, Prof.MD 4, Xavier Muñoz, DrMD 5, Miguel Angel Bergna, DrMD 6, Jay Azmi, DrPhD 7, Dalal Mouneimne, DrPhD 8, Sandra Joksaite, MSc 9, Frank C. Albers, DrMD, PhD 1
1 GSK, Respiratory Medical Franchise, Durham, NC
2 Johns Hopkins Asthma and Allergy Center, Baltimore, MD
3 Capital Allergy and Respiratory Disease Center, Sacramento, CA
4 Asthma & Airway Centre, Toronto, ON, Canada
5 Hospital Universitari Vall d'Hebron, Barcelona, Spain
6 CEMER, Vicente Lopez, Buenos Aires, Argentina
7 Respiratory TAU, GSK, Stockley Park, Uxbridge, United Kingdom
8 GSK, Global Medical Affairs, GSK House, Brentwood, United Kingdom
9 Clinical Statistics, GSK, Stockley Park, Uxbridge, United Kingdom
L30
Le texte complet de cet article est disponible en PDF.Plan
© 2017
Publié par Elsevier Masson SAS.
Vol 141 - N° 2S
P. AB409 - février 2018 Retour au numéro
Article précédent
- Efficacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Asthma Control, Quality of Life and Lung Function Outcomes
- Frank C. Albers, Mark C. Liu, Bradley E. Chipps, Kenneth R. Chapman, Xavier Muñoz, Miguel Angel Bergna, Jay Azmi, Dalal Mouneimne, Sandra Joksaite, Dmitry Galkin
- Best Practices in Recruitment of the First US-Based Atopic Dermatitis Cohort: The Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH).
- Asel Baatyrbek-kyzy, Rosario Alarcon, Alexandria Patterson, Kristina Keidel, John Kroner, Gurjit K. Khurana Hershey, Jocelyn M. Biagini Myers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?